Jones Hill Capital LP

Registered adviser

CIK

2102314

Location

NEW YORK, NY

Portfolio Value

Small $470,359,275

Diversification

Diversified

Filing Date

Global Rank

#3,991 / 8,818 ▼ 304

Top Industry

Biotechnology 83.3%

3Y Alpha vs SPY

-13.2%

Period ended 4 months ago

Filed Aug 13, 2026 · 3mo

2 quarters · since Mar 2026

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Oct 1, 2026

Form ADV adviser

CRD 339686

Roster of Oct 1, 2026

Regulatory AUM

$642,420,587

Main clients

Pooled investment vehicles (100% of AUM)

Private funds

1 fund · Hedge funds

Focus by fund count, roster of Oct 1, 2026

$230,253,160 gross assets

LEI

25490036SLH9ZR3QKG86

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Jun 2026 to Oct 2026	$642,420,587	Pooled investment vehicles (100%)
Feb 2026 to May 2026	$0	—

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Concentrated

The top 10 positions are 68.8% of the book (60%+)

Turnover

Turnover unknown

It needs four straight quarters of measured turnover

Horizon

Short horizon

Value-weighted holding period 1.6 quarters (under 4)

Closest benchmark: the Nasdaq-100 as of 2026-06-30, active share 98.8%; sector active share 90.9% against the combined 13F book's sector weights.

Over time 2 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

29 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

17.4%

+2.1 pts

Top 5

44.3%

−2.0 pts

Top 10

68.8%

−4.2 pts

HHI

682

Diversified−19

Portfolio Trend

2 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	100.0%	$470,359,275	29

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

5 positions

Ticker	Company	Δ Shares	Shares	Value
RLMD	Relmada Therapeutics, Inc.	+3,312,323	3,655,075	$25,293,119
TRVI	Trevi Therapeutics, Inc.	+969,037	1,339,212	$24,976,303
PHVS	Pharvaris N.V.	+510,865	677,879	$23,441,055
TNXP	Tonix Pharmaceuticals Holding Corp.	+173,312	625,428	$7,980,461
BMRN	Biomarin Pharmaceutical Inc	+163,200	1,431,590	$81,915,579
No positions match the current search.

Trimmed

Positions the filer reduced

9 positions

Ticker	Company	Δ Shares	Shares	Value
AMLX	Amylyx Pharmaceuticals, Inc.	−704,736	894,058	$16,057,281
ELVN	Enliven Therapeutics, Inc.	−543,190	49,850	$2,529,887
VIR	Vir Biotechnology, Inc.	−539,000	659,213	$6,717,380
CAPR	Capricor Therapeutics, Inc.	−488,456	420,751	$10,131,684
BCAX	Bicara Therapeutics Inc.	−367,515	892,621	$26,501,917
—		−202,388	98,442	$12,157,587
VRTX	Vertex Pharmaceuticals Inc	−97,480	11,123	$5,525,127
ANIP	Ani Pharmaceuticals Inc	−84,783	233,808	$19,354,626
GPCR	Structure Therapeutics Inc.	−60,026	40,567	$2,177,230
No positions match the current search.

New Positions

Positions the filer opened this quarter

15 positions

Ticker	Company	Shares	Value
GILD	Gilead Sciences, Inc.	343,043	$43,340,052
ARQT	Arcutis Biotherapeutics, Inc.	1,089,701	$28,571,960
MDGL	Madrigal Pharmaceuticals, Inc.	52,545	$28,214,037
XENE	Xenon Pharmaceuticals Inc.	367,900	$22,206,444
IMCR	Immunocore Holdings plc	512,856	$16,283,178
INSM	INSMED Inc	122,375	$13,047,622
ACRS	Aclaris Therapeutics, Inc.	1,759,492	$9,307,712
IMUX	Immunic, Inc.	539,814	$8,296,941
ORIC	Oric Pharmaceuticals, Inc.	747,313	$8,093,399
SNDX	Syndax Pharmaceuticals Inc	340,000	$7,432,400
OLMA	Olema Pharmaceuticals, Inc.	574,166	$7,182,816
CRBP	Corbus Pharmaceuticals Holdings, Inc.	653,572	$6,130,505
DNTH	Dianthus Therapeutics, Inc.	57,100	$5,566,108
PHAT	Phathom Pharmaceuticals, Inc.	161,486	$1,752,123
ACHV	Achieve Life Sciences, Inc.	26,760	$174,742
No positions match the current search.

Sold Out

Positions the filer fully exited

12 positions

Ticker	Company	Shares	Value
PCVX	Vaxcyte, Inc.	644,831	$37,471,129
—		521,237	$27,479,615
RARE	Ultragenyx Pharmaceutical Inc.	1,165,557	$24,418,419
ARGX	Argenx SE	25,995	$18,982,848
FULC	Fulcrum Therapeutics, Inc.	1,771,926	$13,590,672
NUVB	Nuvation Bio Inc.	2,383,031	$10,223,202
ORKA	Oruka Therapeutics, Inc.	140,843	$6,908,349
CTNM	Contineum Therapeutics, Inc.	513,053	$6,700,472
MANE	Veradermics, Inc	100,843	$6,368,235
TRDA	Entrada Therapeutics, Inc.	374,010	$4,720,006
SLN	Silence Therapeutics plc	301,604	$1,589,453
AVBP	ArriVent BioPharma, Inc.	45,809	$1,056,813
No positions match the current search.

Portfolio Positions

Compact Export CSV View 13F filing

29 tracked positions · $470,359,275 total · filing declares 29 positions · $470,359,288 · as of Jun 30, 2026

All sectors Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
BMRN	Biomarin Pharmaceutical Inc Healthcare	Added	1,431,590	+163,200	$81,915,579	+14.3%	2	before history	17.42%
GILD	Gilead Sciences, Inc. Healthcare	NEW	343,043	NEW	$43,340,052	NEW	1	$131.76	9.21%
ARQT	Arcutis Biotherapeutics, Inc. Healthcare	NEW	1,089,701	NEW	$28,571,960	NEW	1	$23.30	6.07%
MDGL	Madrigal Pharmaceuticals, Inc. Healthcare	NEW	52,545	NEW	$28,214,037	NEW	1	$512.24	6.00%
BCAX	Bicara Therapeutics Inc. Healthcare	Reduced	892,621	-367,515	$26,501,917	+5.7%	2	before history	5.63%
RLMD	Relmada Therapeutics, Inc. Healthcare	Added	3,655,075	+3,312,323	$25,293,119	+960.3%	2	before history	5.38%
TRVI	Trevi Therapeutics, Inc. Healthcare	Added	1,339,212	+969,037	$24,976,303	+465.6%	2	before history	5.31%
PHVS	Pharvaris N.V. Healthcare	Added	677,879	+510,865	$23,441,055	+396.8%	2	before history	4.98%
XENE	Xenon Pharmaceuticals Inc. Healthcare	NEW	367,900	NEW	$22,206,444	NEW	1	$55.52	4.72%
ANIP	Ani Pharmaceuticals Inc Healthcare	Reduced	233,808	-84,783	$19,354,626	−21.0%	2	before history	4.11%
IMCR	Immunocore Holdings plc Healthcare	NEW	512,856	NEW	$16,283,178	NEW	1	$29.58	3.46%
AMLX	Amylyx Pharmaceuticals, Inc. Healthcare	Reduced	894,058	-704,736	$16,057,281	−27.7%	2	before history	3.41%
INSM	INSMED Inc Healthcare	NEW	122,375	NEW	$13,047,622	NEW	1	$121.09	2.77%
		Reduced	98,442	-202,388	$12,157,587	−60.6%	2	before history	2.58%
CAPR	Capricor Therapeutics, Inc. Healthcare	Reduced	420,751	-488,456	$10,131,684	−63.3%	2	before history	2.15%
ACRS	Aclaris Therapeutics, Inc. Healthcare	NEW	1,759,492	NEW	$9,307,712	NEW	1	$4.46	1.98%
IMUX	Immunic, Inc. Healthcare	NEW	539,814	NEW	$8,296,941	NEW	1	unpriced	1.76%
ORIC	Oric Pharmaceuticals, Inc. Healthcare	NEW	747,313	NEW	$8,093,399	NEW	1	$9.07	1.72%
TNXP	Tonix Pharmaceuticals Holding Corp. Healthcare	Added	625,428	+173,312	$7,980,461	+28.4%	2	before history	1.70%
SNDX	Syndax Pharmaceuticals Inc Healthcare	NEW	340,000	NEW	$7,432,400	NEW	1	$20.80	1.58%
OLMA	Olema Pharmaceuticals, Inc. Healthcare	NEW	574,166	NEW	$7,182,816	NEW	1	$13.40	1.53%
VIR	Vir Biotechnology, Inc. Healthcare	Reduced	659,213	-539,000	$6,717,380	−37.4%	2	before history	1.43%
CRBP	Corbus Pharmaceuticals Holdings, Inc. Healthcare	NEW	653,572	NEW	$6,130,505	NEW	1	$9.47	1.30%
DNTH	Dianthus Therapeutics, Inc. Healthcare	NEW	57,100	NEW	$5,566,108	NEW	1	$87.34	1.18%
VRTX	Vertex Pharmaceuticals Inc Healthcare	Reduced	11,123	-97,480	$5,525,127	−88.6%	2	before history	1.17%
ELVN	Enliven Therapeutics, Inc. Healthcare	Reduced	49,850	-543,190	$2,529,887	−89.1%	2	before history	0.54%
GPCR	Structure Therapeutics Inc. Healthcare	Reduced	40,567	-60,026	$2,177,230	−55.1%	2	before history	0.46%
PHAT	Phathom Pharmaceuticals, Inc. Healthcare	NEW	161,486	NEW	$1,752,123	NEW	1	$11.41	0.37%
ACHV	Achieve Life Sciences, Inc. Healthcare	NEW	26,760	NEW	$174,742	NEW	1	$4.77	0.04%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.